

Suraksha Diagnostics invests Rs 22 Cr to establish Eastern India's largest genomics lab

05 July 2025 | News

Suraksha's Genomics Lab enables the detection of chromosomal abnormalities



Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-the-art genomics labs in Eastern India with a grand inauguration event which was graced by Prof. Sukumar Mukherjee, a distinguished rheumatologist with more than 35 years of extensive experience in the field and a mentor at Suraksha Diagnostics.

The global genetic testing market is valued at \$38.77 billion (2024) and is projected to reach \$186.64 billion by the year 2035 (CAGR: 22.5%). In a landmark move, Suraksha Diagnostics has invested Rs 22 crore in establishing its Genomics Lab. An additional Rs 46 crore investment is planned over the next 24 months to establish one of Asia's most advanced Genomics Laboratories. This initiative is a significant leap forward for West Bengal, Eastern & North-Eastern India, and India's future in precision diagnostics.

This State-of-the-Art Genomics Lab is equipped with Cytogenetics, Microarray Technology, Sanger Sequencing, Multiple Next-Generation Sequencers (NGS). Together, these technologies enable the full spectrum of advanced genetic testing, offering predictive, preventive, and personalised care.

Suraksha's Genomics Lab enables the detection of chromosomal abnormalities like Down syndrome, Edwards syndrome, and Patau syndrome, as well as sex chromosome aneuploidies and microdeletions. These insights help expecting parents make informed decisions, supported by expert genetic counseling.

Suraksha's Genomics Lab also pioneers Onco-genomics with advanced hereditary cancer testing panels, enabling early detection of genetic predispositions to breast, ovarian, and colorectal cancers. The lab offers both germline and somatic mutation profiling, aiding in personalized cancer risk assessment and treatment planning. With targeted oncology panels

powered by NGS, clinicians can now identify actionable mutations for precision therapies.	